221
Participants
Start Date
August 31, 2012
Primary Completion Date
July 31, 2014
Study Completion Date
July 31, 2014
Viaskin Peanut 50 mcg
Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 50 mcg peanut proteins as whole peanut extract
Viaskin Peanut 100 mcg
Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 100 mcg peanut proteins as whole peanut extract
Viaskin Peanut 250 mcg
Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
Viaskin Placebo
Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing a matching placebo formulation
Children's Hospital of Pittsburgh, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Centre Hospitalier Universitaire de Bordeaux, Hôpital Pellegrin, Bordeaux
Cincinnati Children's Hospital Medical Center, Cincinnati
Hôpitaux De Brabois, Vandœuvre-lès-Nancy
Hôpital Saint Vincent de Paul, Lille
Children's Memorial Hospital, Chicago
Nouvel Hôpital Civil, Strasbourg
Children's Medical Center Dallas, Dallas
Hôpital Necker, Paris
Szpital Uniwersytecki nr2, Bydgoszcz
University of California, Rady Childrens Hospital, San Diego
Szpital Kliniczny UM, Lodz
Stanford University School of Medicine, Stanford
ASTHMA, Inc., Seattle
Massachusetts General Hospital, Boston
Boston Childrens' Hospital, Boston
Cheema Research Inc., Mississauga
Ottawa Allergy Asthma Research Institute, Ottawa
Gordon Sussman Clinical Research, Toronto
Centre de Recherche Appliquée en Asthme et Allergie de Québec, Sainte-Foy
GCS des hôpitaux pédiatriques, Nice
Erasmus MC, Rotterdam
UMC Utrecht, Utrecht
Lead Sponsor
DBV Technologies
INDUSTRY